IDO1 and neoplasm: Another IDO1 inhibitor increased IDO1 activity in tumor cells leading to increased KYN products (Triplett et al., 2018), which suppress CD4+ Th1 cells, Th17 cells, CTLs, and NK cells, all of which are overexpressed in malignant tissue.